TABLE 1

Plasma NEFA, β-hydroxybutyrate, and glycerol concentrations during the overnight euglycemic (90 ± 9 mg/dl) steady-state period (4:00–8:00 a.m.), after 2 days of rhIGF-I/IGFBP-3 complex or placebo given as subcutaneous injection at 6:00 p.m. on each day

Group A (n = 7)
Group B (n = 8)
Dose of rhIGF-I/IGFBP-3Placebo0.1 mg · kg−1 · day−10.4 mg · kg−1 · day−1Placebo0.2 mg · kg−1 · day−10.8 mg · kg−1 · day−1
NEFA AUC1,500 ± 2131,377 ± 1891,514 ± 3051,683 ± 2061,688 ± 2881,326 ± 215
β-hydroxybutyrate AUC0.71 ± 0.140.77 ± 0.210.66 ± 0.231.16 ± 0.200.87 ± 0.190.95 ± 0.26
Glycerol (μmol/l)54.6 ± 4.756.0 ± 7.652.8 ± 7.748.6 ± 8.352.4 ± 6.339.0 ± 7.1
  • Data are mean ± SE. P > 0.05 for all comparisons between placebo and rhIGF-1/IGFBP-3, adjusted for plasma insulin concentration. NEFA and β-hydroxybutyrate determined as area under curve (AUC) between 4:00 and 8:00 a.m. Glycerol concentration determined as mean of repeated samples between 7:30 and 8:00 a.m.